Incyte Corporation INCY
119.18 USD +0.09 (+0.08%)
As ofNov 18, 2026, 12:00 PM EST
118.40 Day range 120.99
90.30 52-week range 129.93
- YTD
- +20.66%
- 1 year
- +14.72%
News
zacks.com INCY Wins European Commission Nod For Skin Disease Drug Incyte secures EC approval for Povofortay, the first once-daily oral HS treatment in the EU, opening a new growth opportunity backed by strong clinical results.
seekingalpha.com Incyte Corporation (INCY) Presents at Jefferies Global Healthcare Conference 2026 Transcript Incyte Corporation (INCY) Presents at Jefferies Global Healthcare Conference 2026 Transcript
reuters.com Incyte says EU approves oral treatment for chronic skin disease Incyte says EU approves oral treatment for chronic skin diseasebenzinga.com STOP-HS1 And STOP-HS2 Trials Evaluating Safety And Efficacy Of Povofortay In Patients With Moderate To Severe HS Met The Primary Endpoint The overall safety profile of Povofortay over 54 weeks was consistent with previously reported data; both doses were well tolerated, with no new or unexpected safety signals. The most frequent TEAEs…
businesswire.com Povofortay® (povorcitinib) Approved in Europe as the First Once-Daily Oral Treatment for Adults with Moderate to Severe Hidradenitis Suppurativa WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Povofortay® (povorcitinib) Approved in Europe as the First Once-Daily Oral Treatment for Adults with Moderate to Severe Hidradenitis Suppurativa.
defenseworld.net Incyte Corporation $INCY Stock Position Cut by Eurizon Capital SGR S.p.A. Eurizon Capital SGR S.p.A. decreased its position in Incyte Corporation (NASDAQ: INCY) by 13.0% during the undefined quarter, according to its most recent filing with the Securities and Exchange…
marketbeat.com Incyte Maps Post-Jakafi Growth, Targeting Up to $4 Billion in Other Sales by 2030 Incyte NASDAQ: INCY is preparing for a transition away from its JAKAFI business, with Chief Executive Officer Bill Meury pointing to product launches and a pipeline of late-stage drug candidates as…benzinga.com Natera Enters Into Clinical Collaboration Agreement With Incyte For New Phase II Study In Colorectal Cancer Trial designed to improve outcomes through Signatera™-guided Treatment on MRD (TOMR), identifying high-risk patients for curative-intent treatmentNatera, Inc. (NASDAQ:NTRA), a global leader in…
benzinga.com Leerink Partners Maintains Outperform on Incyte, Lowers Price Target to $150 Leerink Partners analyst Andrew Berens maintains Incyte (NASDAQ:INCY) with a Outperform and lowers the price target from $154 to $150.
benzinga.com $1000 Invested In Incyte 20 Years Ago Would Be Worth This Much Today Incyte (NASDAQ:INCY) has outperformed the market over the past 20 years by 8.34% on an annualized basis producing an average annual return of 17.11%. Currently, Incyte has a market capitalization of…benzinga.com Incyte To Present New Data On Its 30 Abstracts At American Society Of Hematology Annual Meeting Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstracts at the 2026 American Society of Hematology…
benzinga.com Bernstein Maintains Market Perform on Incyte, Raises Price Target to $108 Bernstein analyst Jeffrey Walch maintains Incyte (NASDAQ:INCY) with a Market Perform and raises the price target from $104 to $108.
benzinga.com Wells Fargo Maintains Equal-Weight on Incyte, Lowers Price Target to $127 Wells Fargo analyst Derek Archila maintains Incyte (NASDAQ:INCY) with a Equal-Weight and lowers the price target from $128 to $127.
benzinga.com RBC Capital Maintains Sector Perform on Incyte, Raises Price Target to $117 RBC Capital analyst Brian Abrahams maintains Incyte (NASDAQ:INCY) with a Sector Perform and raises the price target from $114 to $117.
benzinga.com Barclays Maintains Overweight on Incyte, Raises Price Target to $143 Barclays analyst Etzer Darout maintains Incyte (NASDAQ:INCY) with a Overweight and raises the price target from $139 to $143.
benzinga.com This Monolithic Power Analyst Turns Bullish; Here Are Top 4 Upgrades For Friday Analysts upgraded Incyte, Intel, Rivian and Monolithic Power, raising ratings and targets; MPWR’s target increased to $1,700.benzinga.com Evercore ISI Group Maintains In-Line on Incyte, Raises Price Target to $127 Evercore ISI Group analyst Maneka Mirchandaney maintains Incyte (NASDAQ:INCY) with a In-Line and raises the price target from $125 to $127.
benzinga.com Incyte To Rally More Than 23%? Here Are 10 Top Analyst Forecasts For Friday Analysts raised targets for Cheniere and Incyte, while cutting Stryker, Roblox, Intel and Honeywell; Bright Horizons was downgraded.benzinga.com Oppenheimer Upgrades Incyte to Outperform, Raises Price Target to $144 Oppenheimer analyst Jay Olson upgrades Incyte (NASDAQ:INCY) from Perform to Outperform and raises the price target from $120 to $144.
benzinga.com Incyte Q3 2026 Earnings Call Transcript Incyte (NASDAQ:INCY) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by…benzinga.com Incyte Raises FY2026 Sales Guidance from $5.130B-$5.260B to $5.210B-$5.300B vs $5.929B Est Incyte (NASDAQ:INCY) raises FY2026 sales outlook from $5.130 billion-$5.260 billion to $5.210 billion-$5.300 billion vs $5.929 billion estimate.
benzinga.com Incyte Q3 Adj. EPS $(3.60) Beats $(3.85) Estimate, Sales $1.557B Beat $1.470B Estimate Incyte (NASDAQ:INCY) reported quarterly losses of $(3.60) per share which beat the analyst consensus estimate of $(3.85) by 6.49 percent. This is a 259.29 percent decrease over earnings of $2.26 per…
benzinga.com Genmab's Encouraging Oncology Data Boosts Investor Optimism Genmab shares positive petosemtamab trial data across multiple solid tumors at ESMO and partners with Incyte on targeted colorectal therapy.benzinga.com TD Cowen Maintains Buy on Incyte, Raises Price Target to $140 TD Cowen analyst Tara Bancroft maintains Incyte (NASDAQ:INCY) with a Buy and raises the price target from $138 to $140.
finance.yahoo.com Quantinuum Inc. (QNT) Quantinuum’s latest update combined record bookings, higher revenue guidance, and progress toward fault-tolerant quantum systems. Japan partnerships with RIKEN and SoftBank broaden its quantum-AI ...
allsci.com EU approves Incyte's oral JAK1 inhibitor Povofortay for hidradenitis suppurativa The European Commission has approved Incyte's Povofortay (povorcitinib) as the first once-daily oral treatment for adults with moderate to severe ...
finance.yahoo.com INCY Wins European Commission Nod For Skin Disease Drug Incyte secures EC approval for Povofortay, the first once-daily oral HS treatment in the EU, opening a new growth opportunity ...
fidelity.co.uk Incyte Corp (INCY) Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with ...
finance.yahoo.com CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression…
seekingalpha.com Quant ratings on Bridgewater Associates' top holdings: SPY, IVV, NVDA, AVGO Bridgewater Associates adds Dominion and Occidental, exits Union Pacific and Paccar, cuts Google 83% and Microsoft 80%, and raises its Netflix stake 733%.
rttnews.com Incyte Wins European Approval For Povofortay In Hidradentis Suppurativa Incyte ( INCY) announced that the European Commission has approved Povofortay (povorcitinib) 45 mg and 75 mg for eligible adults with moderate-to-severe hidradenitis suppurativa, a chronic ...
crowdfundinsider.com SEC Opens Inquiry into Nvidia’s Disclosures Following Jensen Huang’s Exit Federal regulators have opened a civil inquiry into Nvidia (NASDAQ: NVDA) focused on whether the semiconductor giant’s public ...
seekingalpha.com Incyte Corporation (INCY) Presents at UBS Global Biopharma Conference 2026 Transcript UBS Global Biopharma Conference 2026 November 17, 2026 8:20 AM ESTCompany ParticipantsPablo Cagnoni - President and Global Head ...
marketscreener.com Incyte Insider Sold Shares Worth $1,292,032, According to a Recent SEC Filing Incyte Corporation specializes in the research & development of therapeutic products mainly intended for the treatment of ...
crowdfundinsider.com Intel ($INTC) Lawsuit Over 29% Single-Day Plunge May Have Implications for AMD and Nvidia Intel (NASDAQ: INTC) shareholders have filed a proposed class-action lawsuit accusing the chipmaker of misleading investors ...
marketscreener.com Transcript : Incyte Corporation Presents at UBS Global Biopharma Conference 2026, Nov-17-2026 01:20 PM All right. Good day, everybody. Welcome to UBS Biopharma Conference in London. Next company with me here Incyte Therapeutics. And I'm really excited to present ...
marketscreener.com Transcript : Incyte Corporation Presents at Jefferies Global Healthcare Conference 2026, Nov-17-2026 09:00 AM [Audio Gap] biotech analyst at Jefferies. We are here in London at the Jefferies Global Healthcare Conference. Thank you all ...
